

DAFTAR PUSTAKA

- Agarwal, S., & Agarwal, S. K. (2021). Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. *Cardiovascular Drugs and Therapy*, 35(3), 427–440. <https://doi.org/10.1007/s10557-020-07070-1>
- Agrawal, U., Raju, R., & Udawadia, Z. F. (2020). Favipiravir: A new and emerging antiviral option in COVID-19. In *Medical Journal Armed Forces India* (Vol. 76, Issue 4). <https://doi.org/10.1016/j.mjafi.2020.08.004>
- Alsanosi, S. M. M., Skiffington, C., & Padmanabhan, S. (2014). Pharmacokinetic Pharmacogenomics. *Handbook of Pharmacogenomics and Stratified Medicine*, 341–364. <https://doi.org/10.1016/B978-0-12-386882-4.00017-7>
- Ashraf, M. (2012). Handbook of Drug Interactions: a Clinical and Forensic Guide. *British Journal of Clinical Pharmacology*. <https://doi.org/10.1111/j.1365-2125.2012.04264.x>
- Avery A. Barron, Rachel J. Kirsch, Neil B. Sandson, Wayne T. Nicholson, & Catherine Marcucci MD. (2020, June). *Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation*. <https://www.apsf.org/article/experimental-covid-19-therapy-combination-lopinavir-ritonavir-is-implicated-in-a-complicated-set-of-drug-drug-interactions/>
- Bjerrum, L., Lopez-Valcarcel, B. G., & Petersen, G. (2008). Risk factors for potential drug interactions in general practice. *European Journal of General Practice*. <https://doi.org/10.1080/13814780701815116>
- Bushra, R., Aslam, N., & Khan, A. Y. (2011). Food-drug interactions. In *Oman Medical Journal*. <https://doi.org/10.5001/omj.2011.21>
- Bwire, G. M. (2020). Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? *SN Comprehensive Clinical Medicine*, 2(7). <https://doi.org/10.1007/s42399-020-00341-w>
- Cantudo-Cuenca, M. D., Gutiérrez-Pizarraya, A., Pinilla-Fernández, A., Contreras-Macías, E., Fernández-Fuertes, M., Lao-Domínguez, F. A., Rincón, P., Pineda, J. A., Macías, J., & Morillo-Verdugo, R. (2021). Drug–drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. *Scientific Reports*. <https://doi.org/10.1038/s41598-021-91953-2>
- Cao, Y. chen, Deng, Q. xin, & Dai, S. xue. (2020). Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. In *Travel Medicine and Infectious Disease*. <https://doi.org/10.1016/j.tmaid.2020.101647>
- Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, Evaluation and Treatment Coronavirus (COVID-19). In *StatPearls*.

- Cascorbi, I. (2012). Drug interactions--principles, examples and clinical consequences. *Deutsches Ärzteblatt International*. <https://doi.org/10.3238/arztebl.2012.0546>
- Cattaneo, D., Pasina, L., Conti, F., Giacomelli, A., Oreni, L., Pezzati, L., Bonazzetti, C., Piscaglia, M., Carrozzo, G., Antinori, S., & Gervasoni, C. (2021). Risks of potential drug–drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience. *Journal of Endocrinological Investigation*. <https://doi.org/10.1007/s40618-021-01604-6>
- Cattaneo, Dario, Pasina, L., Maggioni, A. Pietro, Giacomelli, A., Oreni, L., Covizzi, A., Bradanini, L., Schiuma, M., Antinori, S., Ridolfo, A., & Gervasoni, C. (2020). Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. *Drugs and Aging*. <https://doi.org/10.1007/s40266-020-00812-8>
- Choy, K. T., Wong, A. Y. L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P. H., Huang, X., Peiris, M., & Yen, H. L. (2020). Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Research*. <https://doi.org/10.1016/j.antiviral.2020.104786>
- Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.-C., Wang, C.-B., & Bernardini, S. (2020). The COVID-19 pandemic. *Critical Reviews in Clinical Laboratory Sciences*, 57(6), 365–388. <https://doi.org/10.1080/10408363.2020.1783198>
- Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L. R., Schwartz, A., & Uriel, N. (2020). COVID-19 and Cardiovascular Disease. *Circulation*, 141(20), 1648–1655. <https://doi.org/10.1161/CIRCULATIONAHA.120.046941>
- Deb, S., Reeves, A. A., Hopefl, R., & Bejusca, R. (2021). Adme and pharmacokinetic properties of remdesivir: Its drug interaction potential. In *Pharmaceuticals*. <https://doi.org/10.3390/ph14070655>
- Dias, B. M., Dos Santos, F. S., & Reis, A. M. M. (2019). Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: Cross-sectional study. *Sao Paulo Medical Journal*, 137(4). <https://doi.org/10.1590/1516-3180.2019.013405072019>
- Djharuddin, I., Munawwarah, S., Nurulita, A., Ilyas, M., Tabri, N. A., & Lihawa, N. (2021). Comorbidities and mortality in COVID-19 patients. *Gaceta Sanitaria*, 35. <https://doi.org/10.1016/j.gaceta.2021.10.085>
- Drugs.com. (2023a). *Drug Interaction Report: cefoperazone, lopinavir / ritonavir*. https://www.drugs.com/interactions-check.php?drug_list=548-0,1484-0
- Drugs.com. (2023b). *Paxlovid and remdesivir Interactions - Drugs.com*. <https://www.drugs.com/drug-interactions/paxlovid-with-remdesivir-4326-19915-4146-0.html?professional=1>

- Elsevier. (2023). *Elsevier – Drug Monograph | Nirmatrelvir; Ritonavir*. <https://elsevier.health/en-US/preview/nirmatrelvir-ritonavir>
- Fahmia, R., Helda, H., & Nursari, A. Y. (2022). Lama Rawat Inap Pasien Terkonfirmasi COVID-19 di Rumah Sakit Universitas Indonesia dan Faktor yang Mempengaruhinya. *Jurnal Epidemiologi Kesehatan Indonesia*, 6(1), 1–12. <https://doi.org/10.7454/epidkes.v6i1.5004>
- Fang, X., Li, S., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H., & Ma, X. (2020). Epidemiological, comorbidity factors with severity and prognosis of COVID-19: A systematic review and meta-analysis. *Aging*. <https://doi.org/10.18632/aging.103579>
- Farzam, K., & Tivakaran, V. S. (2022). QT Prolonging Drugs. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK534864/>
- Fitrianto, H., Azmi, S., & Kadri, H. (2014). Penggunaan Obat Antihipertensi pada Pasien Hipertensi Esensial di Poliklinik Ginjal Hipertensi RSUP DR. M. Djamil Tahun 2011. *Jurnal Kesehatan Andalas*. <https://doi.org/10.25077/jka.v3i1.24>
- Francis, P., & Navarro, V. J. (2022). Drug Induced Hepatotoxicity. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK557535/>
- Gandhi, Z., Mansuri, Z., & Bansod, S. (2020). Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective. *SN Comprehensive Clinical Medicine*, 2(10), 1707–1708. <https://doi.org/10.1007/s42399-020-00462-2>
- Goldman, J., Sullins, A., Sandritter, T., Leeder, J. S., & Lowry, J. (2013). Pediatric Pharmacovigilance Enhancing Adverse Drug Reaction Reporting in a Tertiary Care Children's Hospital. *Therapeutic Innovation & Regulatory Science*, 47, 566–571. <https://doi.org/10.1177/2168479013499153>
- Han, K., Cao, P., Wang, Y., Xie, F., Ma, J., Yu, M., Wang, J., Xu, Y., Zhang, Y., & Wan, J. (2022). A Review of Approaches for Predicting Drug–Drug Interactions Based on Machine Learning. In *Frontiers in Pharmacology*. <https://doi.org/10.3389/fphar.2021.814858>
- Hansten, P. D., Horn, J. R., & Korth-Bradley, J. M. (2010). The Top 100 Drug Interactions: A Guide to Patient Management, 2010 Edition. *Annals of Pharmacotherapy*. <https://doi.org/10.1345/aph.1p108>
- Hodge, C., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., Burger, D., Back, D., & Khoo, S. (2020). Drug interactions: A review of the unseen danger of experimental COVID-19 therapies. In *Journal of Antimicrobial Chemotherapy*. <https://doi.org/10.1093/jac/dkaa340>
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)

- Iloanusi, S., Mgbere, O., & Essien, E. J. (2021). Polypharmacy among COVID-19 patients: A systematic review. *Journal of the American Pharmacists Association : JAPhA*, 61(5), e14–e25. <https://doi.org/10.1016/j.japh.2021.05.006>
- Ivan H, S. (2008). Stockley 's Drug Interactions. *Pharmaceutical Press*.
- Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020). Virology, epidemiology, pathogenesis, and control of covid-19. In *Viruses*. <https://doi.org/10.3390/v12040372>
- Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021). Role of favipiravir in the treatment of COVID-19. In *International Journal of Infectious Diseases*. <https://doi.org/10.1016/j.ijid.2020.10.069>
- Journey, J. D., Agrawal, S., & Stern, E. (2022). Dextromethorphan Toxicity. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK538502/>
- Katzung, B., & Trevor, A. (2015). Katzung's Basic & Clinical Pharmacology. In *Basic and clinical Pharmacology*.
- Kluwer, W. (2022). Lexicomp® Drug Interactions - UpToDate. In *Lexi-Interact Online*.
- Kohler, G. I., Bode-Boger, S. M., Busse, R., Hoopmann, M., Welte, T., & Boger, R. H. (2000). Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug use. *International Journal of Clinical Pharmacology and Therapeutics*, 38(11). <https://doi.org/10.5414/CP38504>
- KPCPEN. (2022). *Peta Sebaran. Satuan Tugas Penanganan COVID-19*. KPCPEN. <https://covid19.go.id/>
- Krustev, T., Milushewa, P., & Tachkov, K. (2022). Impact of Polypharmacy, Drug-Related Problems, and Potentially Inappropriate Medications in Geriatric Patients and Its Implications for Bulgaria-Narrative Review and Meta-Analysis. In *Frontiers in public health* (Vol. 10, p. 743138). <https://doi.org/10.3389/fpubh.2022.743138>
- Kumar, D., & Trivedi, N. (2021). Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. In *Biomedicine and Pharmacotherapy*. <https://doi.org/10.1016/j.biopha.2021.111642>
- Kumar, M., & Al Khodor, S. (2020). Pathophysiology and treatment strategies for COVID-19. In *Journal of Translational Medicine* (Vol. 18, Issue 1). <https://doi.org/10.1186/s12967-020-02520-8>
- Kusumawardani, L. A., Maria, N., & Fanani, Y. N. (2021). Potential drug interactions analysis of COVID-19 patients at a hospital in West Java Analisis potensi interaksi obat pada pasien rawat inap COVID-19 pada suatu rumah sakit di Jawa Barat. *Jurnal Ilmiah Farmasi (Scientific Journal of Pharmacy)*, 17(2), 181–196. <http://journal.uii.ac.id/index.php/JIF>
- Lee, G. A., Lo, J. C., Aweeka, F., Schwarz, J.-M., Mulligan, K., Schambelan, M.,

- & Grunfeld, C. (2006). Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. *Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America*, 43(5), 658–660. <https://doi.org/10.1086/505974>
- Levani, Prastya, & Mawaddatunnadila. (2021). Coronavirus Disease 2019 (COVID-19): Patogenesis, Manifestasi Klinis dan Pilihan Terapi. *Jurnal Kedokteran Dan Kesehatan*.
- Lexicomp. (2023a). *Antidiabetic Agents/Hyperglycemia-Associated Agents: Drug Interaction*. https://www.upToDate.com/drug-interactions/?source=responsive_home#di-document
- Lexicomp. (2023b). *Favipiravir/Theophylline: Drug Interaction*. UpToDate.
- Lexicomp. (2023c). *Lopinavir/Ritonavir / Dextromethorphan : Drug Interaction*. UpToDate.
- Lexicomp. (2023d). *Metronidazole/Lopinavir/ritonavir: Drug Interaction*.
- Lexicomp. (2023e). *Oseltamivir/Clopidogrel: Drug Interactions*. UpToDate.
- Lexicomp. (2023f). *Oseltamivir/Favipiravir: Drug Interaction*. UpToDate.
- Lexicomp. (2023g). *Pyrazinamide / Favipiravir: Drug Interactions*. UpToDate.
- Lexicomp. (2023h). *Remdesivir/Rifampicin: Drug Interactionn*. UpToDate.
- Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., Zhang, Q., & Wu, J. (2020). Coronavirus infections and immune responses. In *Journal of Medical Virology*. <https://doi.org/10.1002/jmv.25685>
- Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. In *Journal of Pharmaceutical Analysis*. <https://doi.org/10.1016/j.jpha.2020.03.001>
- Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020). COVID-19: Transmission, prevention, and potential therapeutic opportunities. In *Clinica Chimica Acta*. <https://doi.org/10.1016/j.cca.2020.05.044>
- Mahboobipour, A. A., & Baniasadi, S. (2021). Clinically important drug–drug interactions in patients admitted to hospital with COVID-19: Drug pairs, risk factors, and management. *Drug Metabolism and Personalized Therapy*, 36(1), 9–16. <https://doi.org/10.1515/dmpt-2020-0145>
- Manjhi, P. K., Kumar, R., Priya, A., & Rab, I. (2021). Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India. *Maedica*. <https://doi.org/10.26574/maedica.2021.16.2.163>
- Maulidia, S. S., Mahmudah, F., & Sastyarina, Y. (2021). Kajian Potensi Interaksi Obat pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda. *Proceeding of Mulawarman Pharmaceuticals Conferences*. <https://doi.org/10.25026/mpc.v14i1.587>
- Meini, S., Pagotto, A., Longo, B., Vendramin, I., Pecori, D., & Tascini, C. (2020).

- Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. In *Journal of Clinical Medicine* (Vol. 9, Issue 7). <https://doi.org/10.3390/jcm9072050>
- Melenotte, C., Silvin, A., Goubet, A. G., Lahmar, I., Dubuisson, A., Zumla, A., Raoult, D., Merad, M., Gachot, B., Hénon, C., Solary, E., Fontenay, M., André, F., Maeurer, M., Ippolito, G., Piacentini, M., Wang, F. S., Ginhoux, F., Marabelle, A., ... Zitvogel, L. (2020). Immune responses during COVID-19 infection. In *OncoImmunology*. <https://doi.org/10.1080/2162402X.2020.1807836>
- Monod, M., Blenkinsop, A., Xi, X., Hebert, D., Bershan, S., Tietze, S., Baguelin, M., Bradley, V. C., Chen, Y., Coupland, H., Filippi, S., Ish-Horowicz, J., McManus, M., Mellan, T., Gandy, A., Hutchinson, M., Unwin, H. J., van Elsland, S. L., Vollmer, M. A. C., ... Ratmann, O. (2021). Age groups that sustain resurging COVID-19 epidemics in the United States. *Science*, 371(6536). <https://doi.org/10.1126/SCIENCE.ABE8372>
- Mousavi, S., & Ghanbari, G. (2017). Potential drug-drug interactions among hospitalized patients in a developing country. *Caspian Journal of Internal Medicine*, 8(4). <https://doi.org/10.22088/cjim.8.4.282>
- Mueller, A. L., Mcnamara, M. S., & Sinclair, D. A. (2020). Why does COVID-19 disproportionately affect older people? In *Aging* (Vol. 12, Issue 10). <https://doi.org/10.18632/aging.103344>
- Mukherjee, S., & Pahan, K. (2021). *Is COVID-19 Gender-sensitive?* 38–47.
- Nigam, S. K., Bush, K. T., Martovetsky, G., Ahn, S.-Y., Liu, H. C., Richard, E., Bhatnagar, V., & Wu, W. (2015). The organic anion transporter (OAT) family: a systems biology perspective. *Physiological Reviews*, 95(1), 83–123. <https://doi.org/10.1152/physrev.00025.2013>
- Obach, R. S., Huynh, P., Allen, M. C., & Beedham, C. (2004). Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs. *Journal of Clinical Pharmacology*. <https://doi.org/10.1177/0091270003260336>
- PDPI. (2020). Tatalaksana Pasien Covid-19. *Perhimpunan Dokter Paru Indonesia*, 19, 19–21.
- Ramos-Esquivel, A., Fernández, C., Garro-Zamora, L., Chaves, A. V., & Viquez-Jaikel, Á. (2022). High Prevalence of Potential Drug-Drug Interactions Among Patients Treated with Off-label Therapies for COVID-19. *Journal of Pharmaceutical Care*, 2–5. <https://doi.org/10.18502/jpc.v10i2.9972>
- Rizk, J. G., Effron, M. B., Jr, J. G. L., & Lavie, C. J. (2022). *Proposal for a Simple Algorithmic Approach to Manage Drug – Drug Interactions of Oral Anticoagulants with Nirmatrelvir / Ritonavir in COVID-19 Outpatients*. 21201, 6–9.
- Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., Hosein, Z., Padda, I., Mangat, J., & Altaf, M. (2020). Comorbidity and its Impact on Patients with COVID-19. *SN Comprehensive Clinical Medicine*.

<https://doi.org/10.1007/s42399-020-00363-4>

- Schurink, B., Roos, E., Radonic, T., Barbe, E., Bouman, C. S. C., de Boer, H. H., de Bree, G. J., Bulle, E. B., Aronica, E. M., Florquin, S., Fronczek, J., Heunks, L. M. A., de Jong, M. D., Guo, L., du Long, R., Lutter, R., Molenaar, P. C. G., Neefjes-Borst, E. A., Niessen, H. W. M., ... Bugiani, M. (2020). Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. *The Lancet Microbe*, 1(7), e290–e299. [https://doi.org/10.1016/S2666-5247\(20\)30144-0](https://doi.org/10.1016/S2666-5247(20)30144-0)
- Sevrioukova, I. F., & Poulos, T. L. (2013). Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. *Dalton Transactions (Cambridge, England: 2003)*, 42(9), 3116–3126. <https://doi.org/10.1039/c2dt31833d>
- Shah, H., & Shah, N. J. (2019). *Drug Interactions BT - Introduction to Basics of Pharmacology and Toxicology: Volume 1: General and Molecular Pharmacology: Principles of Drug Action* (G. M. Raj & R. Raveendran (eds.); pp. 197–204). Springer Singapore. https://doi.org/10.1007/978-981-32-9779-1_12
- Shah, S. B., Hariharan, U., & Chawla, R. (2021). Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents. In *Journal of Anaesthesiology Clinical Pharmacology* (Vol. 37, Issue 2). https://doi.org/10.4103/joacp.JOACP_461_20
- Shah, S. P., Patel, K. M., Subedi, R., & Gambhir, H. S. (2017). Review of potential drug interaction between Oseltamivir and Warfarin and why it is important for emergency medicine physicians. *American Journal of Emergency Medicine*. <https://doi.org/10.1016/j.ajem.2017.03.040>
- Shetty, V., Chowta, M. N., Chowta K, N., Shenoy, A., Kamath, A., & Kamath, P. (2018). Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital. *Journal of Aging Research*, 2018. <https://doi.org/10.1155/2018/5728957>
- Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., Wang, Q., Wolfe, L., Jordan, R., Soloveva, V., Knox, J., Perry, J., Perron, M., Stray, K. M., Barauskas, O., ... Mackman, R. L. (2017). Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. *Journal of Medicinal Chemistry*. <https://doi.org/10.1021/acs.jmedchem.6b01594>
- Snyder, S. R., Favoretto, A. M., Baetz, R. A., Derzon, J. H., Madison, B. M., Mass, D., Shaw, C. S., Layfield, C. D., Christenson, R. H., & Liebow, E. B. (2012). Effectiveness of practices to reduce blood culture contamination: A Laboratory Medicine Best Practices systematic review and meta-analysis. In *Clinical Biochemistry*. <https://doi.org/10.1016/j.clinbiochem.2012.06.007>
- Spanakis, M., Patelarou, A., Patelarou, E., & Tzanakis, N. (2021). Drug interactions for patients with respiratory diseases receiving covid-19 emerged treatments.

International Journal of Environmental Research and Public Health, 18(21).
<https://doi.org/10.3390/ijerph182111711>

- Tejaswi, P., Devashish, K., & Prasad, R. R. (2021). Pharmacological effects of favipiravir on coronavirus: An update. In *Biomedical and Pharmacology Journal* (Vol. 14, Issue 2). <https://doi.org/10.13005/bpj/2212>
- U.S. Food and Drug Administration. (2021). FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR. *US Food & Drug Administration (FDA)*.
- Urquhart, B. L., & Nolin, T. D. (2020). Drug Metabolism in Chronic Kidney Disease. *Chronic Renal Disease*, 1035–1051. <https://doi.org/10.1016/B978-0-12-815876-0.00063-2>
- Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020). A novel coronavirus outbreak of global health concern. In *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30185-9](https://doi.org/10.1016/S0140-6736(20)30185-9)
- WHO. (2022). *WHO Coronavirus Disease (COVID-19) Dashboard*. <https://covid19.who.int/>
- Wolff, D., Nee, S., Hickey, N. S., & Marschollek, M. (2021). Risk factors for Covid-19 severity and fatality: a structured literature review. In *Infection* (Vol. 49, Issue 1). <https://doi.org/10.1007/s15010-020-01509-1>
- Zhao, Y., Harmatz, J. S., Epstein, C. R., Nakagawa, Y., Kurosaki, C., Nakamura, T., Kadota, T., Giesing, D., Court, M. H., & Greenblatt, D. J. (2015). Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. *British Journal of Clinical Pharmacology*, 80(5). <https://doi.org/10.1111/bcp.12644>
- Zumla, A., Hui, D. S., Azhar, E. I., Memish, Z. A., & Maeurer, M. (2020). Reducing mortality from 2019-nCoV: host-directed therapies should be an option. In *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30305-6](https://doi.org/10.1016/S0140-6736(20)30305-6)